Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3, indicating a new release.
    Difference
    0.0%
    Check dated 2024-09-04T05:18:20.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    The website has been updated from version v2.10.0 to v2.10.2.
    Difference
    0.0%
    Check dated 2024-08-13T23:44:45.000Z thumbnail image
  5. Check
    28 days ago
    No Change Detected
  6. Check
    41 days ago
    Change Detected
    Summary
    A new resource titled 'Helpful Links Provided by Andrea Ardizzoni' has been added, featuring information on Cabozantinib (XL184), highlighting its role as a novel MET and VEGFR2 inhibitor that suppresses metastasis, angiogenesis, and tumor growth.
    Difference
    0.6%
    Check dated 2024-07-25T17:17:37.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The study has expanded to include 11 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-23T14:45:14.000Z thumbnail image
  8. Check
    50 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T08:34:02.000Z thumbnail image
  9. Check
    61 days ago
    Change Detected
    Summary
    The website has removed information about Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, and helpful links provided by Andrea Ardizzoni from the University of Bologna.
    Difference
    0.6%
    Check dated 2024-07-05T17:24:03.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.